An exterior view of the premises of Jumpcan Holdings Group. [Photo/WeChat account: txfabu]
Jumpcan Holdings Group in the Taixing Economic Development Zone in Taixing city – administered by Taizhou in East China's Jiangsu province – recently ranked 35th among the Top 100 list of China's pharmaceutical industry in 2022.
The achievement was announced at the 2023 Conference of the Development of China's Pharmaceutical Industry, held in Beijing on Nov 18.
Founded in 1994, Jumpcan covers traditional Chinese and Western medicine, Chinese medicine cosmetics and the traditional Chinese medicine healthcare sectors.
It focuses on drug research and development, production and sales in the fields of pediatrics, gynecology – as well as respiratory, digestive and geriatric diseases – continuously expanding its range of traditional Chinese medicine cosmetics and health products.
More than 10 varieties the company developed are exclusive in the country, recognized as being high-tech products and leading brand products in Jiangsu province.
Jumpcan promotes the entrepreneurial spirit of "helping each other in the same boat and being tolerant to diversity" and the core ethical values of "innovation, hard work and win-win".